NUVATION BIO
nuvationbio.com
Actively hiring
Oncology Therapeutics
As featured in
View 1 job
Claim pageClaim
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Jobs
Financials
News
Nuvation Bio (NUVB) Receives a Buy from RBC Capital
Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.
Read more
Report
Nuvation Bio Announces Fda Approval of Supplemental New Drug Application for Ibtrozi (Taletrectinib) with Updated Duration of Response in Tki-Naive Advanced Ros1-Positive Non ...
Read more
Report
Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups
Nuvation Bio (NYSE:NUVB) presented new subgroup analyses of IBTROZI (taletrectinib) at the 2026 World Conference on Lung Cancer. The data indicated durable and consistent efficacy in advanced ROS1+ non small cell lung cancer regardless of prior chemothera
Read more
Report
Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-II
The post Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-II appeared first on NUVATION BIO, INC..
Read more
Report
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Comparative Efficacy of Taletrectinib Versus First-Generation TKIs in TKI-Naïve ROS1+ Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison
The post Comparative Efficacy of Taletrectinib Versus First-Generation TKIs in TKI-Naïve ROS1+ Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison appeared first on NUVATION BIO, INC..
Read more
Report
Nuvation Bio Expands Convertible Notes Offering and Financing
Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.
Read more
Report
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
NEW YORK, June 25, 2026 Nuvation Bio Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering of $250.0 million aggregate principal amount of 0.75% Co
Read more
Report
Patient-Reported Outcomes and Health-Related Quality of Life With Taletrectinib in Advanced ROS1+ NSCLC From the TRUST-II Study
The post Patient-Reported Outcomes and Health-Related Quality of Life With Taletrectinib in Advanced ROS1+ NSCLC From the TRUST-II Study appeared first on NUVATION BIO, INC..
Read more
Report
Randomized, Double-Blind, Phase 3 TRUST-IV Study of Adjuvant Taletrectinib vs Placebo in Patients With Stage IB-IIIA ROS1+ Non-Small Cell Lung Cancer (NSCLC)
The post Randomized, Double-Blind, Phase 3 TRUST-IV Study of Adjuvant Taletrectinib vs Placebo in Patients With Stage IB-IIIA ROS1+ Non-Small Cell Lung Cancer (NSCLC) appeared first on NUVATION BIO, INC..
Read more
Report
Show more news
Tech stack
Technologies named in job postings at NUVATION BIO over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Practices & domains
GMP
Sign in to see how your skills match this stack
Sign In
People
David Hung M.D.
Executive Officer, Director
Kim Blickenstaff
Director
Michelle Doig
Director
Kathryn Falberg
Director
Claudio Nessi
Director
W. Vernon
Director
Daniel Welch
Director
Robert Bazemore
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
22/100
Hiring freeze
Open positions
1
0 opened / 0 closed in 30 days
Median time-to-fill
119 days
faster than 11% of the market
ATS activity
Every ~5 hours
Today
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
100% ▲
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
2
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Shanghai
China
Regional office
China
118 Ruijin Second Road, Huangpu District,, Shanghai 200021, China
Jobs
Equity • Remote (United States) • Full-Time • 10+ years exp • United States
GMP
Apply
Financials
Total raised
$275.3M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2019 | $275.3M | Details |